Étiquette : AML
-
Advanced BioDesign to Present Groundbreaking Research data on AML at the 67th ASH Annual Meeting
Lyon, France – December 5th, 2025 — Advanced BioDesign, a French clinical-stage biotechnology company focused on developing innovative therapies for treatment-resistant cancers, is proud to announce its participation at the American Society of Hematology (ASH) Annual Meeting 2025 with two significant scientific contributions. Oral Presentation Title: Anthracyclines induce epigenetic changes in ALDH1A that promote chemoresistance…
-
Media Coverage: Advanced BioDesign Featured in Le Figaro: Accelerating Innovation Against Resistant Cancers
Advanced BioDesign is honored to be featured in Le Figaro Économie, which highlights our cutting-edge approach to overcoming cancer resistance through targeted inhibition of ALDH1—a key enzyme that enables tumor survival and relapse. Our lead compound, ABD-3001, currently in Phase 1 clinical trials for acute myeloid leukemia (AML), has shown promising biological activity even at…
-
Advanced BioDesign Announces Publication in HemaSphere Uncovering Novel Mechanism Driving Chemoresistance in Acute Myeloid Leukemia
Lyon, France – November 6th, 2025 – Advanced BioDesign, a French clinical-stage biotechnology company focused on developing innovative therapies for treatment-resistant cancers, today announced the publication of its latest research in HemaSphere, the official journal of the European Hematology Association. The article, titled “Upregulation of ALDH1 as an adaptive epigenetic response to anthracyclines in acute…
Advanced BioDesign 